Supernus Pharmaceuticals Inc Forecasted to Earn Q1 2020 Earnings of $0.32 Per Share (SUPN)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – Equities research analysts at Piper Jaffray Companies lowered their Q1 2020 earnings per share estimates for Supernus Pharmaceuticals in a report released on Wednesday, May 8th. Piper Jaffray Companies analyst D. Amsellem now anticipates that the specialty pharmaceutical company will post earnings per share of $0.32 for the quarter, down from their prior estimate of $0.52. Piper Jaffray Companies currently has a “Hold” rating and a $44.00 price target on the stock. Piper Jaffray Companies also issued estimates for Supernus Pharmaceuticals’ FY2020 earnings at $2.56 EPS, FY2021 earnings at $3.70 EPS, FY2022 earnings at $5.18 EPS and FY2023 earnings at $2.94 EPS.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 earnings per share for the quarter, missing the consensus estimate of $0.44 by ($0.10). The company had revenue of $85.50 million for the quarter, compared to analysts’ expectations of $102.26 million. Supernus Pharmaceuticals had a net margin of 27.14% and a return on equity of 27.45%. The company’s revenue was down 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.49 earnings per share.

Several other equities research analysts have also recently weighed in on the company. Zacks Investment Research cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Cantor Fitzgerald set a $57.00 price objective on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, January 10th. ValuEngine cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. BidaskClub cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 22nd. Finally, B. Riley set a $65.00 price objective on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, March 4th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. Supernus Pharmaceuticals has an average rating of “Hold” and a consensus target price of $56.13.

Shares of SUPN stock opened at $36.50 on Friday. The stock has a market cap of $1.94 billion, a P/E ratio of 17.80 and a beta of 1.57. Supernus Pharmaceuticals has a 1-year low of $30.05 and a 1-year high of $61.25. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.06 and a quick ratio of 2.90.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Menta Capital LLC lifted its stake in shares of Supernus Pharmaceuticals by 3.5% in the 4th quarter. Menta Capital LLC now owns 7,824 shares of the specialty pharmaceutical company’s stock valued at $260,000 after purchasing an additional 265 shares during the period. Victory Capital Management Inc. increased its position in Supernus Pharmaceuticals by 4.1% during the 4th quarter. Victory Capital Management Inc. now owns 7,536 shares of the specialty pharmaceutical company’s stock valued at $250,000 after buying an additional 296 shares in the last quarter. Advisor Group Inc. increased its position in Supernus Pharmaceuticals by 17.2% during the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 306 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in Supernus Pharmaceuticals by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 20,239 shares of the specialty pharmaceutical company’s stock valued at $709,000 after buying an additional 366 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. increased its position in Supernus Pharmaceuticals by 2.5% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 16,567 shares of the specialty pharmaceutical company’s stock valued at $581,000 after buying an additional 397 shares in the last quarter. Institutional investors own 98.62% of the company’s stock.

In other news, CFO Gregory S. Patrick sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $41.53, for a total value of $830,600.00. Following the completion of the transaction, the chief financial officer now owns 67,896 shares in the company, valued at approximately $2,819,720.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 6.20% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Recommended Story: Book Value Per Share in Stock Trading

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.